A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982)
Summary
The purpose of this pilot study is to compare the use of deep or standard neuromuscular blockade (NMB) in combination with low or standard insufflation pressure in participants undergoing a surgical procedure, laparoscopic cholecystectomy. Insufflation refers to the injection of carbon dioxide into the abdomen during the laparoscopic surgery, to allow visualization of and access to the surgical field. The primary hypothesis of the study is that the use of sustained deep NMB improves the surgeon's overall satisfaction with surgical conditions as compared to standard NMB. The in-patient surgery is performed on Day 1 and the participant remains hospitalized for at least 48 hours following the surgery (or at least 24 hours following the surgery, if local practice does not allow 48 hours of hospitalization post surgery). On Day 8, a follow-up visit/contact including all participants occurs.
Timeline
- Start
- 2012-11-28
- Primary completion
- 2014-04-29
- Completion
- 2014-04-29
Outcome
Met primary endpoint
registry analysis (superiority or other test); Standard NMB vs Deep NMB; p = 0.026; Difference in Least Squares (LS) Means 1.09 (95% CI 0.13 to 2.04); ANCOVA NCT01728584 ↗
registry analysis (superiority or other test); Standard Insufflation Pressure vs Low Insufflation Pressure; p <0.001; Difference in LS Means -3.02 (95% CI -3.99 to -2.05); ANCOVA NCT01728584 ↗
paper Surgeon's score of overall satisfaction with surgical conditions was significantly higher with deep versus moderate NMB indicated by a least-square mean difference of 1.1 points (95% confidence interval 0.1-2.0; P = 0.026). PMID 28251555 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rocuronium | Other / unclassified | 0.45 mg/kg | Intravenous |
| Background | Sugammadex | Other / unclassified | 2 mg/kg | Intravenous |
| Background | Sugammadex | Other / unclassified | 4 mg/kg | Intravenous |